Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > So the LIFE financing gave them the minimum $3,5M CAD
View:
Post by Rumpl3StiltSkin on Nov 17, 2023 8:21pm

So the LIFE financing gave them the minimum $3,5M CAD

right? And this new financing is to get the rest of the ~$5M CAD?
Comment by james700 on Nov 18, 2023 2:46am
The Company also announces that it has mutually terminated the recently announced brokered Listed Issuer Financing Exemption ("LIFE") financing with Research Capital Corporation. This was in the News Release... My personal guess... So, it would appear that they did not raise $3.5M and are planning on a smaller $1.5M raise, through a different method.
Comment by Rumpl3StiltSkin on Nov 18, 2023 10:59am
thanks James,  That makes sense. I guess they have some $$$ to make it through to BTD. Then, hopefully, they'll get a nice JV...
Comment by lscfa on Nov 18, 2023 11:32am
Theralase dropped the issue size from $3.5 - $5 mil to $1.5 mil......As $1.5 mil does not give the co. available funds for 12 months it can't do a LIFE (with no restricted period). Instead it must do a private placement with a 4 month hold period.
Comment by BudFoxx2020 on Nov 18, 2023 11:44am
LIFE financing was a dud and scrapped when RCC would not go out of its way to push it.  So only thing left to do is to do was a regular PP.   A much smaller one at that.  1.5 million.  NO it has not been filled, it is just the same promoters putting their spin on it as usual.  The previous PP they struggled to fill 1 million and I believe management took 20% of it ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250